Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Management of Sepsis and Septic Shock
Respiratory guidelines--which real world?
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Risk of Procedural Hemorrhage.
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
See All 7 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Results (36)
More Search Options
Sort
Query Relevance
Name (A-Z)
Name (Z-A)
Institution (A-Z)
Institution (Z-A)
Show
(choose columns)
Institution
Department
Faculty Rank
Name
Institution
Why
Scott E. Eggener
University of Chicago
Why?
Simon Hayward
University of Chicago
Why?
Rachel Myers
University of Chicago
Why?
Ted Skolarus
University of Chicago
Why?
Mark Abe
University of Chicago
Why?
James J. Dignam
University of Chicago
Why?
Gladell P. Paner
University of Chicago
Why?
Abhinav Sidana
University of Chicago
Why?
Tatjana Antic
University of Chicago
Why?
Andrea Olivas
University of Chicago
Why?
Robert M. Naclerio
University of Chicago
Why?
Daniel H. Shevrin
University of Chicago
Why?
Carole Ober
University of Chicago
Why?
Walter M. Stadler
University of Chicago
Why?
Dan Liviu Nicolae
University of Chicago
Why?
Per Page
15
25
50
100
Page
of 3
Next
Prev
Search Criteria
Kallikreins
Click "Why?" to see why a person matched the search.
Search Options
Modify Search
Search Other Institutions